8-K: Ekso Bionics Secures $5.3M in Private Placement

Ekso Bionics Holdings, Inc. completed a private placement of Series B Convertible Preferred Stock and warrants, raising approximately $5.3 million in net proceeds for working capital.

Summary

• Ekso Bionics Holdings, Inc. (EKSO) entered into securities purchase agreements on January 20, 2026, for a private placement that closed on January 22, 2026.
• The company issued 5,852 shares of Series B Convertible Preferred Stock, each with a stated value of $1,000, convertible into 711,922 shares of common stock at $8.22 per share.
• Warrants to purchase up to an aggregate of 355,960 shares of common stock were also issued, with an exercise price of $8.22 per share.
• Lake Street Capital Markets, LLC served as the exclusive placement agent, receiving a cash fee of 6.0% of gross proceeds (approximately $0.4 million) and a warrant to purchase 14,238 shares of common stock.
• Net proceeds from the private placement are expected to be approximately $5.3 million, which will be used for working capital and general corporate purposes.
• The Series B Preferred Stock has a liquidation preference of $1,000 per share, ranks senior to common stock, and is junior to existing and future debt.
• Holders of Series B Preferred Stock vote on an as-converted basis with common stock, subject to a 19.99% voting cap (or 9.99% for individual holders), unless stockholder approval or a Nasdaq waiver is obtained.
• The Series B Preferred Stock is redeemable at the company's or holder's option at the stated value starting January 22, 2027, or at the holder's option upon a 'Trading Failure' event.
• The company agreed to file a registration statement for the resale of the conversion shares and warrant shares by June 1, 2026, and use commercially reasonable efforts to have it declared effective within 30-60 days.
• Transfer restrictions apply to the newly issued securities, prohibiting transfer or short sales until six months post-closing or two trading days after a change of control, with limited exceptions.

Sentiment

Score: 6

Explanation: The filing indicates a successful capital raise, providing necessary funds for the company's operations and growth. While there is potential for dilution, the financing secures immediate liquidity and demonstrates investor confidence. The protective provisions for preferred stockholders are also a positive.

Positives

• The private placement provides approximately $5.3 million in net proceeds, bolstering the company's working capital and general corporate purposes.
• The issuance of Series B Preferred Stock and Warrants demonstrates investor confidence in the company's future prospects.
• The company has committed to filing a registration statement for the resale of the underlying common stock, providing a path to liquidity for investors.
• The Series B Preferred Stock includes protective provisions requiring majority holder approval for actions that would adversely affect its rights, offering a degree of investor protection.

Negatives

• The issuance of preferred stock and warrants could lead to significant dilution for existing common stockholders upon conversion and exercise.
• The 6.0% placement agent fee and other offering expenses reduce the net proceeds received by the company, impacting the efficiency of the capital raise.
• Transfer restrictions on the newly issued securities limit immediate liquidity for the purchasers for at least six months.
• The beneficial ownership limitation (9.99% for individual holders, 19.99% aggregate) restricts the ability of large investors to convert or exercise their securities without further approvals or waivers.

Risks

• Failure to obtain an effective registration statement by the specified deadlines could result in liquidated damages payable to purchasers.
• The company's ability to maintain its Nasdaq listing is crucial, as a 'Trading Failure' could trigger redemption rights for preferred stockholders.
• The beneficial ownership limitations could hinder the full conversion or exercise of securities by large holders, potentially impacting their investment strategy.
• The marketability of the common stock could be affected by the potential future sales of a large number of shares upon conversion of preferred stock and exercise of warrants.

Future Outlook

The company intends to use the net proceeds from this private placement for working capital and general corporate purposes, which suggests a focus on ongoing operations and potential growth initiatives. The commitment to file a registration statement for resale indicates a future path for investors to monetize their holdings.

Management Comments

• Jerome Wong, Chief Financial Officer, signed the Form 8-K.
• Scott G. Davis, Chief Executive Officer, signed the Certificate of Designation.

Industry Context

This private placement provides Ekso Bionics with additional capital, which is common for growth-stage companies in the medical device or robotics industry that require ongoing investment in R&D, market expansion, or operational scaling. The terms, including conversion features and warrants, are typical for such financing rounds, attracting institutional and accredited investors seeking potential upside while providing some downside protection through preferred stock features.

Comparison to Industry Standards

• The 6.0% placement agent fee is within the customary range for private placements of this size in the industry, which typically varies based on the amount raised and the complexity of the transaction.
• The conversion and exercise prices of $8.22 per share for the preferred stock and warrants are set at a specific valuation, which would need to be compared against recent trading prices and peer valuations to assess its competitiveness.
• The beneficial ownership limitations (9.99% individual, 19.99% aggregate) are standard provisions often included in private placements to manage potential control changes and comply with exchange rules like Nasdaq's Rule 5635(b).

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution upon conversion of preferred stock and exercise of warrants. Existing common shareholders' voting power could be diluted.
• Investors (Purchasers): Gain preferred stock with liquidation preference and redemption rights, along with warrants for additional upside. Subject to transfer restrictions and beneficial ownership limitations.
• Company: Receives capital for working capital and general corporate purposes, strengthening its financial position. Incurs obligations related to registration rights and potential liquidated damages.
• Placement Agent: Earns a cash fee and warrants for facilitating the private placement.

Next Steps

• The company will use the net proceeds for working capital and general corporate purposes.
• The company is obligated to prepare and file a registration statement with the SEC by June 1, 2026, for the resale of the Conversion Shares and Warrant Shares.
• The company will use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, within 30 days (or 60 days if reviewed by the SEC).
• Warrants will become exercisable starting on July 22, 2026.
• The Series B Preferred Stock becomes redeemable at the company's or holder's option starting January 22, 2027.

Key Dates

Recommendation

The private placement provides Ekso Bionics with much-needed capital for working capital and general corporate purposes, which is a positive for the company's operational stability and growth initiatives. However, the significant potential for dilution from the conversion of preferred stock and exercise of warrants, coupled with the associated fees, introduces uncertainty for existing common shareholders. The protective provisions for preferred stockholders are favorable for those investors but could constrain future corporate flexibility. Given the capital infusion and the future dilution potential, a 'hold' recommendation is appropriate, advising investors to monitor the company's use of funds and the market's absorption of the new shares upon registration and conversion/exercise.

Keywords

Private Placement, Series B Preferred Stock, Warrants, Capital Raise, SEC Filing, Equity Financing, Dilution, Registration Rights, Corporate Governance, Nasdaq Listing